Friday, October 10, 2025 6:26:07 PM
How exactly do you expect human proof of safety or efficacy when FDA has not yet authorized human use of RadioGel?
The purpose of the IDE submission process is precisely to gain FDA authorization to begin human studies so that safety and efficacy can be demonstrated under regulatory supervision.
What has been proven already.... and documented.... are:
• IsoPet has been successfully and safely used in veterinary oncology for multiple cancer types.
• Those animal results, along with GLP biocompatibility and dosimetry studies, form the scientific basis for the human IDE.
• The FDA’s Center for Devices and Radiological Health (CDRH) already classified RadioGel® as a medical device, not a drug — meaning safety is assessed by physical performance and containment of radiation, both of which have been validated in bench and animal testing.
So saying it “hasn’t proven to work safely” is a circular argument. You can’t have human proof until FDA allows human trials, and you can’t have human trials until the IDE is cleared — that’s exactly the regulatory step Vivos is now following.
$RDGL
The purpose of the IDE submission process is precisely to gain FDA authorization to begin human studies so that safety and efficacy can be demonstrated under regulatory supervision.
What has been proven already.... and documented.... are:
• IsoPet has been successfully and safely used in veterinary oncology for multiple cancer types.
• Those animal results, along with GLP biocompatibility and dosimetry studies, form the scientific basis for the human IDE.
• The FDA’s Center for Devices and Radiological Health (CDRH) already classified RadioGel® as a medical device, not a drug — meaning safety is assessed by physical performance and containment of radiation, both of which have been validated in bench and animal testing.
So saying it “hasn’t proven to work safely” is a circular argument. You can’t have human proof until FDA allows human trials, and you can’t have human trials until the IDE is cleared — that’s exactly the regulatory step Vivos is now following.
$RDGL
Know what you own, and know why you own it.
Recent RDGL News
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2025 09:14:29 PM
